Vaccination against meningococcal B disease. Public statement of the Advisory Committee on Vaccines of the Spanish Association of Paediatrics (CAV-AEP)

• Published in: Anales de pediatría (Barcelona, Spain : 2003) Vol. 82; no. 3; pp. 198.e1 - 198.e9
• Main Authors: Moreno-Pérez, D, Álvarez García, F J, Arístegui Fernández, J, Cilleruelo Ortega, M J, Corretger Rauet, J M, García Sánchez, N, Hernández Merino, A, Hernández-Sampelayo Matos, T, Merino Moína, M, Ortigosa Del Castillo, L, Ruiz-Contreras, J
• Format: Journal Article
• Language: Spanish
• Published: Spain 01.03.2015
• Subjects: Child; Europe; Humans; Meningitis, Meningococcal - prevention & control; Meningococcal Vaccines; Neisseria meningitidis, Serogroup B; Enfermedad meningocócica; Niños; Vacunas; Meningitis; Sepsis; Neisseria meningitidis serogrupo B; Children; Vaccines; Neisseria meningitidis serogroup B; Meningococcal disease
• ISSN: 1695-9531
• DOI: 10.1016/j.anpedi.2014.09.004

Meningococcal invasive disease, including the main clinical presentation forms (sepsis and meningitis), is a severe and potentially lethal infection caused by different serogroups of Neisseria meningitidis. Meningococcal serogroup B is the most prevalent in Europe. Most cases occur in children, with a mortality rate of 10% and a risk of permanent sequelae of 20-30% among survivors. The highest incidence and case fatality rates are observed in healthy children under 2-3 years old, followed by adolescents, although it can occur at any age. With the arrival in Spain of the only available vaccine against meningococcus B, the Advisory Committee on Vaccines of the Spanish Association of Paediatrics has analysed its preventive potential in detail, as well as its peculiar administrative situation in Spain. The purpose of this document is to publish the statement of the Committee as regards this vaccination and the access to it by the Spanish population, taking into account that it has been only authorized for people at risk. The vaccine is available free in the rest of Europe for those who want to acquire it, and in some countries and regions it has been introduced into the systematic immunisation schedules. The Committee considers that Bexsero® has a profile of a vaccine to be included in the official schedules of all the Spanish autonomous communities and insists on the need for it to be available in pharmacies for its administration in all children older than 2 months.